Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice
1998

Tau Expression and Docetaxel Sensitivity in Tumors

Sample size: 7 publication Evidence: moderate

Author Information

Author(s): R Veitia, M-C Bissery, C Martinez, A Fellous

Primary Institution: Institut Pasteur

Hypothesis

Can the expression levels of Tau and microtubule components explain the sensitivity of tumors to docetaxel?

Conclusion

Higher levels of Tau isoforms in docetaxel-sensitive tumors may serve as markers for drug sensitivity.

Supporting Evidence

  • Docetaxel was found to be active on three out of four mammary tumors and one out of two pancreatic tumors.
  • Sensitive tumors showed higher levels of Tau mRNA compared to refractory tumors.
  • Complete tumor regressions were observed in several sensitive tumor models after docetaxel treatment.

Takeaway

This study looked at how certain proteins in tumors affect their response to a cancer drug called docetaxel, finding that more of a protein called Tau means the tumors are more likely to respond to the drug.

Methodology

The study used RT-PCR and Western blot analysis to assess the expression of microtubule-associated proteins and tubulin isoforms in various tumor models.

Limitations

The study primarily focused on murine models, which may not fully represent human tumor behavior.

Participant Demographics

The study involved various murine tumor models, including mammary and pancreatic adenocarcinomas.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication